This result is in accordance with Yu-Ching Lin, et al. The anthors found that the combination of IR and CK2 inhibitors TBB, TBCA or Hematein can reduce the viability of non-small cell lung cancer cells19. This evidence concerns the gene TBCA and non-small cell lung carcinoma.